|
|
4449 Easton Way, 2nd Floor
Columbus, OH 43219 United States
phone:650-430-8291
fax:
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
2006 |
| Employees |
4 |
|
|
| www.endosphere-inc.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Endoscopically Implantable Devices for the Treatment of Metabolic Disorders |
|
| Management |
| James McKinley, CEO |
| |
|
|
| |
|
| Keywords |
| endoscopy, implant, surgery, obesity, diabetes, appetite control, duodenum, glucose |
|
|
|
| Description |
|
EndoSphere is developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes. |
|
| Products / Services |
EndoSphere's devices boost the natural functions of the duodenum, including control of appetite and regulation of glucose production. The first products now in trials exert effects by virtue of their physical presence, slowing the passage of food to increase signaling. Later products may include more active forms of intervention, including release of bioactive materials and electrical stimulation of neurons.
|
|
| Technology / Differentiation |
| EndoSphere's technology works naturally to cause weight-loss without the cost and complications of surgery. Patients notice only that they feel full sooner and do not feel the need to snack between meals. There are no symptoms of nausea, pain or discomfort that are commonly experienced with other technologies. EndoSphere's products are in human trials outside the United States and are not yet approved for sale. |
|
| Market / Customers |
Obesity is a metabolic disorder affecting 70 million people in the U.S. alone. The World Health Organization (WHO) estimates that worldwide obesity levels will rise to 700 million in 2015, from a current value of 400 million. Obesity is commonly associated with type 2 diabetes, which currently affects 7.8% of the American population (or approximately 23 million people, according to the American Diabetes Association.
|
|
| Funding |
| The company expects to close a $7-10 million Series A round in the next 6 months. |
|
| Status |
| EndoSphere has commenced human testing. The company successfully completed its initial trial outside the U.S. and is now preparing for more extensive trials in Switzerland. It expects to gain approval to market the devices outside the U.S. within 18 months and FDA approval within four years. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members